• 1
    Olsen AH, Njor SH, Vejborg I, et al. A model for determining the effect of mammography service screening. Acta Oncol 2005; 44: 1208.
  • 2
    Olsen AH, Njor SH, Vejborg I, et al. Breast cancer mortality in Copenhagen after introduction of mammography screening: cohort study. Br Med J 2005; 330: 220.
  • 3
    Lynge E, Braaten T, Njor SH, et al. Mammography activity in Norway 1983–2008. Acta Oncol 2011; 50: 10627.
  • 4
    Weedon-Fekjær H, Sørum R, Brenn MK. Hormone use may explain recent results regarding tumor regression. Arch Intern Med 2009; 169: 9967.
  • 5
    Nyström L, Andersson I, Bjurstam N, et al. Long-term effects of mammography screening: updated overview of the Swedish randomised trials. Lancet 2002; 359: 90919.
  • 6
    Tabar L, Fagerberg CJ, Gad A, et al. Reduction in mortality from breast cancer after mass screening with mammography. Randomised trial from the Breast Cancer Screening Working Group of the Swedish National Board of health and Welfare. Lancet 1985; 1: 82932.
  • 7
    Weedon-Fekjær H, Lindqvist BH, Vatten LJ, et al. Estimating mean sojourn time and screening sensitivity using questionnaire data on time since previous screening. J Med Screen 2008; 15: 8390.
  • 8
    Weedon-Fekjær H, Bakken K, Vatten LJ, et al. Understanding recent trends in incidence of invasive breast cancer in Norway: age-period-cohort analysis based on registry data on mammography screening and hormone treatment use. Br Med J 2012; 344: e299 (doi: 10.1136/bmj.e299).
  • 9
    International Agency for Research on Cancer. Breast cancer screening. IARC handbook of cancer prevention. Lyon, France: IARC Press, 2002.
  • 10
  • 11
    Kalager M, Haldorsen T, Bretthauer M, et al. Improved breast cancer survival following introduction of an organised mammography screening program among both screened and unscreened women: a population-based cohort study. Breast Cancer Res 2009; 11: R44 (doi:10.1186/bcr2331).
  • 12
    Kalager M, Zelen M, Langmark F, et al. Effect of screening mammography on breast-cancer mortality in Norway. N Engl J Med 2010; 363: 120310.
  • 13
    Autier P, Boniol M, Gavin A, et al. Breast cancer mortality in neighbouring European countries with different levels of screening but similar access to treatment: trend analysis of WHO mortality database. Br Med J 2011; 343: d4411 (doi: 10.1136/bmj.d4411).
  • 14
    Zahl PH, Strand BH, Mæhlen J. Incidence of breast cancer in Norway and Sweden during introduction of nationwide screening: prospective cohort study. Br Med J 2004; 328: 9214.
  • 15
    Duffy S, Lynge E, Jonsson H, et al. Complexities in the estimation of overdiagnosis in breast cancer screening. Br J Cancer 2008; 99: 11768.
  • 16
    Sørum R, Hofvind S, Skaane P, et al. Trends in incidence of ductal carcinoma in situ: the effect of a population-based screening programme. Breast 2010; 19: 499505.
  • 17
    Utzon-Frank N, Vejborg I, von Euler-Chelpin M, et al. Balancing sensitivity and specificity: sixteen years' of experience from the mammography screening programme in Copenhagen, Denmark. Cancer Epidemiol 2011; 35: 3938.
  • 18
    Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Eng J Med 2005; 353: 178492.
  • 19
    Perry N, Broeders M, de Wolf C, et al., eds. European guidelines for quality assurance in breast cancer screening and diagnosis, 4th edn. Luxembourg: Office for Official Publications of the European Communities, 2006.
  • 20
    Hofvind S, Sørum R, Thoresen S. Incidence and tumor characteristics of breast cancer diagnosed before and after implementation of a population-based screening-program. Acta Oncol 2008; 47: 22531.
  • 21
    Hofvind S, Geller B, Vaek PM, et al. Using the European guidelines to evaluate the Norwegian breast cancer screening program. Eur J Epidemiol 2007; 22: 44755.